MARKET

WVE

WVE

WAVE LIFE SCIENC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.08
+0.23
+3.93%
Closed 16:00 09/23 EDT
OPEN
5.86
PREV CLOSE
5.85
HIGH
6.11
LOW
5.83
VOLUME
153.43K
TURNOVER
--
52 WEEK HIGH
12.17
52 WEEK LOW
4.820
MARKET CAP
308.66M
P/E (TTM)
-1.9659
1D
5D
1M
3M
1Y
5Y
Wave Life Sciences To Present At Chardan Genetic Medicines Conference Monday, Oct. 4, 2021 At 2 p.m. EDT
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD,
Benzinga · 1d ago
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is...
GlobeNewswire · 1d ago
10 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie
In this article, we will take a look at 10 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie. You can skip our detailed analysis of Lee Ainslie’s history, investment strategy, and hedge fund performance, and go directly to s...
Insider Monkey · 3d ago
WAVE Life Sciences, Seelos Therapeutics Shares Up ~11% Following Earlier STAT News Article 'Facing pressure from ALS patients and advocates, the FDA does about-face on review of potential treatment'
https://www.statnews.com/2021/09/15/facing-pressure-from-als-patients-and-advocates-the-fda-does-about-face-on-review-of-potential-treatment/
Benzinga · 09/15 14:51
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
Only clinical-stage candidate for Huntington’s disease designed to selectively lower mutant HTT and spare wild-type HTT Adaptive trial design to enable faster optimization of dosing and decision-making on next steps for WVE-003; data to be generated throug...
GlobeNewswire · 09/09 12:30
WAVE Life Sciences Begins Dosing in Phase 1b/2a Trial of Potential Drug for Huntington's Disease
MT Newswires · 09/09 10:47
Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDTCAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments ...
GlobeNewswire · 09/08 12:30
Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is...
GlobeNewswire · 09/07 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of WVE. Analyze the recent business situations of WAVE LIFE SCIENC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average WVE stock price target is 9.86 with a high estimate of 17.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 54.42M
% Owned: 107.20%
Shares Outstanding: 50.77M
TypeInstitutionsShares
Increased
29
2.42M
New
16
1.20M
Decreased
28
2.59M
Sold Out
31
2.27M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
Christian Henry
President/Chief Executive Officer/Director
Paul Bolno
Chief Financial Officer
Kyle Moran
Senior Vice President
Christopher Francis
Chief Technology Officer
Chandra Vargeese
Other
Michael Panzara
Director
Gregory Verdine
Independent Director
Mark Corrigan
Independent Director
Peter Kolchinsky
Independent Director
Adrian Rawcliffe
Independent Director
Ken Takanashi
Independent Director
Aik Na Tan
Independent Director
Heidi Wagner
No Data
About WVE
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

Webull offers kinds of Wave Life Sciences Ltd stock information, including NASDAQ:WVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading WVE stock methods without spending real money on the virtual paper trading platform.